1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Neurological Diagnostic and Monitoring Equipment Devices Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Neurological Diagnostic and Monitoring Equipment Market, United States
3.1 Neurological Diagnostic and Monitoring Equipment Market, United States, Revenue ($m), 2018-2033
3.1.1 Electrical Activity Testing Market, United States, Revenue ($m), by Segment, 2018-2033
3.1.2 ICP Monitoring Devices Market, United States, Revenue ($m), by Segment, 2018-2033
3.2 Neurological Diagnostic and Monitoring Equipment Market, United States, Volume (Units), 2018-2033
3.2.1 Electrical Activity Testing Market, United States, Volume (Units), by Segment, 2018-2033
3.2.2 ICP Monitoring Devices Market, United States, Volume (Units), by Segment, 2018-2033
3.3 Neurological Diagnostic and Monitoring Equipment Market, United States, Average Price ($), 2018-2033
3.4 Neurological Diagnostic and Monitoring Equipment Market, United States, Company Share by Revenue ($m), 2025
4 Overview of Key Companies in United States, Neurological Diagnostic and Monitoring Equipment Market
4.1 Natus Medical Inc
4.1.1 Company Overview
4.2 Nihon Kohden Corp
4.2.1 Company Overview
4.3 Medtronic Plc
4.3.1 Company Overview
4.4 Masimo Corp
4.4.1 Company Overview
4.5 Cadwell Industries Inc
4.5.1 Company Overview
4.6 Integra LifeSciences Corp
4.6.1 Company Overview
4.7 Compumedics Ltd
4.7.1 Company Overview
4.8 Megin Oy
4.8.1 Company Overview
4.9 ANT Neuro BV
4.9.1 Company Overview
5 Neurological Diagnostic and Monitoring Equipment Market Pipeline Products6 Recent Developments
6.1 Corporate Communications
6.1.1 Jan 08, 2026: Natus Sensory Appoints Arne Boye Nielsen to Board of Directors
6.1.2 Nov 21, 2025: Stroke Prevention Study CREST-2 Stenting
6.1.3 Nov 20, 2025: PhotoPharmics Exceeds Enrollment Goal with 350 Participants in Remote Phase 3 Clinical Trial for Parkinson’s Disease
6.1.4 Nov 19, 2025: Renowned Neuromuscular Expert to Lead New NYU Langone ALS Center
6.1.5 Nov 05, 2025: Genesys Strike Negotiations Update
6.1.6 Nov 05, 2025: W&L Expands Parental Leave Benefits for Faculty and Staff
6.1.7 Nov 04, 2025: BrainScope Appoints Matt Adams as Chief Executive Officer
6.1.8 Oct 30, 2025: End Brain Cancer Initiative Partners with Exvade Bioscience to Raise Awareness of Brain Cancer Study
6.1.9 Oct 30, 2025: Siddiqui Performs World’s First Robotic Microsurgical Intracranial Brain Surgery
6.1.10 Oct 24, 2025: Payman Khales Becomes Integer President and CEO
6.1.11 Oct 21, 2025: Laura Jane Ramsburg Appointed Director of Staniar Gallery
6.1.12 Oct 17, 2025: W&L Welcomes New Trustees Thomas J. Sheehan and Andrew W. Tate
6.1.13 Oct 07, 2025: Altoida Expands Advisory Board with Global Leaders in AI, Pharma, and Alzheimer’s Advocacy
6.1.14 Oct 01, 2025: College of Nursing and Public Health Advisory Board Welcomes Marc Adler and Jennifer McIntosh
6.1.15 Sep 24, 2025: CWSL Alumna Sherry S. Bahrambeygui Elected to UC San Diego Foundation Board
6.1.16 Sep 12, 2025: Christina J. Yang, MD, Joins Hassenfeld Children’s Hospital as Chief of Pediatric Otolaryngology
6.1.17 Sep 12, 2025: Renowned Specialist to Lead New Dry Eye Service at NYU Langone Eye Center
6.1.18 Sep 08, 2025: UC San Diego Foundation Announces New Trustees
6.1.19 May 16, 2025: Magstim Granted EU MDR Certification
6.2 Financial Announcements
6.2.1 Sep 25, 2025: Integer Announces Conference Call to Discuss Third Quarter 2025 Results
6.2.2 May 05, 2025: Integra LifeSciences Reports First Quarter 2025 Financial Results
6.2.3 Apr 18, 2025: Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025
6.2.4 Apr 17, 2025: GE HealthCare to Announce First Quarter 2025 Results on April 30, 2025
6.2.5 Feb 04, 2025: Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025
6.3 Government and Public Interest
6.3.1 Dec 01, 2025: Integra LifeSciences Leadership to Present at Citi 2025 Global Healthcare Conference
6.3.2 Nov 17, 2025: GE HealthCare Management to Present at Upcoming Investor Conference
6.3.3 Oct 29, 2025: Seer to Participate in Upcoming November Investor Conferences
6.3.4 Sep 25, 2025: Integer Announces Conference Call to Discuss Third Quarter 2025 Results
6.3.5 Sep 24, 2025: Eysz Announces Positive Results of NIH-Funded Study on Novel Absence Seizure Screening Tool
6.3.6 Aug 29, 2025: Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences
6.3.7 Aug 21, 2025: GE HealthCare Management to Present at Upcoming Investor Conferences
6.3.8 Aug 12, 2025: Integer to Present at 2025 Wells Fargo Healthcare Conference on Sept. 4
6.3.9 Feb 10, 2025: GE Healthcare Management to Present at Upcoming Investor Conference
6.4 Other Significant Developments
6.4.1 Nov 24, 2025: NeuroPace Announces Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
6.4.2 Nov 10, 2025: Hope Therapeutics, Inc. Announces First-in-Florida Initiation of One Day Depression Treatment
6.4.3 Oct 24, 2025: Laser Procedure Offers Solutions For Epilepsy And Brain Tumors
6.4.4 Jun 02, 2025: Listening to Lives Behind the Numbers: Linus Health Study Champions Person-Centered Brain Health Assessments
6.5 Product News
6.5.1 Jan 14, 2026: Integer to Showcase Innovations in Neuromodulation, Miniaturized Active Implantable Device Technology During NANS 2026 Annual Meeting
6.5.2 Nov 26, 2025: Neuro Event Labs Receives FDA 510(k) Clearance for Nelli Seizure Monitoring System
6.5.3 Nov 20, 2025: PhotoPharmics Exceeds Enrollment Goal with 350 Participants in Remote Phase 3 Clinical Trial for Parkinson’s Disease
6.5.4 Nov 18, 2025: QuantalX Receives FDA De Novo Clearance for Delphi-MD
6.5.5 Nov 15, 2025: Evidence Builds for Disrupted Mitochondria as Cause of Parkinson’s
6.5.6 Nov 10, 2025: URI Team Develops Tabletop Device to Study Long-Term Effects of Traumatic Brain Injury
6.5.7 Nov 05, 2025: MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer’s Patients
6.5.8 Oct 30, 2025: Siddiqui Performs World’s First Robotic Microsurgical Intracranial Brain Surgery
6.5.9 Oct 29, 2025: FDA-Approved Focused Ultrasound Treatment for Essential Tremor Now Used for Parkinson's
6.5.10 Oct 21, 2025: Nexalin’s DIFS Neurostimulation Demonstrates Cognitive Improvements in Alzheimer’s and Dementia
6.5.11 Oct 20, 2025: Neupulse Partnership Introduces Innovative Wearable for Tourette Syndrome
6.5.12 Oct 15, 2025: XRHealth Receives U.S. Patent for Advanced XR System Measuring Upper-Limb Impairments
6.5.13 Oct 07, 2025: Brain Stimulation May Reduce Cannabis Addiction in People with Multiple Sclerosis
6.5.14 Sep 24, 2025: Eysz Announces Positive Results of NIH-Funded Study on Novel Absence Seizure Screening Tool
6.5.15 Sep 23, 2025: FDA Clears Cionic Neural Sleeve 2 For Enhanced Mobility Care
6.5.16 Jul 28, 2025: Anywhere powered by Linus Health Expands Equitable Access to Early Detection of Cognitive Impairment
6.5.17 Mar 18, 2025: Anywhere for Health Systems Delivers Clinical-Grade Cognitive Assessments Remotely
7 Appendix
7.1 Research Methodology
7.1.1 Coverage
7.1.2 Secondary Research
7.1.3 Primary Research
7.1.4 Market Modeling and Forecasting
7.1.5 Company Share Analysis
7.1.6 Benchmarking
7.2 the analyst Consulting
7.3 Contact the Publisher
7.4 Disclaimer
List of Tables
Table 1: Neurological Diagnostic and Monitoring Equipment Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 2: Electrical Activity Testing Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 3: ICP Monitoring Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 4: Neurological Diagnostic and Monitoring Equipment Market, United States, Volume (Units), 2018-2033
Table 5: Electrical Activity Testing Market, United States, Volume (Units), 2018-2033
Table 6: ICP Monitoring Devices Market, United States, Volume (Units), 2018-2033
Table 7: Neurological Diagnostic and Monitoring Equipment Market, United States, Average Price ($), 2018-2033
Table 8: Neurological Diagnostic and Monitoring Equipment Market, United States, Company Share by Revenue ($m), 2025
Table 9: Neurological Diagnostic and Monitoring Equipment Market Pipeline Products
Table 10: Total Number of Primary Research Participants, Neurology Devices Market, by Country
List of Figures
Figure 1: Neurological Diagnostic and Monitoring Equipment Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 2: Electrical Activity Testing Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 3: ICP Monitoring Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 4: Neurological Diagnostic and Monitoring Equipment Market, United States, Volume (Units), 2018-2033
Figure 5: Electrical Activity Testing Market, United States, Volume (Units), 2018-2033
Figure 6: ICP Monitoring Devices Market, United States, Volume (Units), 2018-2033
Figure 7: Neurological Diagnostic and Monitoring Equipment Market, United States, Company Share (%), 2025